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Abstract: Evidence that whey proteins and peptides have health benefits beyond basic infant nutrition
has increased dramatically in recent years. Previously, we demonstrated that a whey-derived
immunoglobulin G-enriched powder (IGEP) enhanced adhesion of Bifidobacterium longum subsp.
infantis ATCC 15697 (B. infantis) to HT-29 cells. In this study, we investigated the synergistic effect of
IGEP-treated B. infantis on preventing the attachment of highly invasive Campylobacter jejuni 81–176
(C. jejuni) to intestinal HT-29 cells. The combination decreased the adherence of C. jejuni to the HT-29
cells by an average of 48% compared to the control (non-IGEP-treated B. infantis). We also confirmed
that treatment of IGEP with sodium metaperiodate, which disables the biological recognition of the
conjugated oligosaccharides, reduced adhesion of B. infantis to the intestinal cells. Thus, glycosylation
of the IGEP components may be important in enhancing B. infantis adhesion. Interestingly, an increased
adhesion phenotype was not observed when B. infantis was treated with bovine serum-derived IgG,
suggesting that bioactivity was unique to milk-derived immunoglobulin-rich powders. Notably,
IGEP did not induce growth of B. infantis within a 24 hours incubation period, as demonstrated by
growth curves and metabolite analysis. The current study provides insight into the functionality of
bovine whey components and highlights their potential in positively impacting the development of a
healthy microbiota.
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1. Introduction
Whey derived from cows’ milk contains many similar components to those found in human
milk and for this reason, is a key ingredient in a wide variety of infant formulas. While breastfeeding
is preferred, infant formulas containing whey proteins are currently the best alternative when
breastfeeding is not an option [1]. Emerging evidence from in vitro, animal, and a small number
of human studies indicate that a variety of beneficial bioactivities are linked to whey protein and
its derivative forms, i.e., concentrate, isolate, hydrolysate, and individual proteins and peptides [1].
Whey proteins are suggested to play a role in influencing the infant gut microbiota. Bifidobacteria
are strong colonizers of the infant gut and an array of bifidobacterial strains can utilize milk glycans
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as substrates for growth [2–5]. High levels of beneficial bacterial species such as bifidobacteria are
present in the breast-fed infants’ gut, inhibiting the growth of pathogenic microorganisms, modulating
the mucosal barrier function, and promoting inflammatory and immunological responses [6]. Balmer
et al. [7] showed that infants ingesting a whey-protein formula had higher levels of bifidobacteria in
their stool compared to those who received a casein-predominant formula at two weeks of age [7].
Similarly, a German-based double-blind study randomized 102 healthy infants under two weeks of
age and demonstrated that whey protein-fed infants had more abundant counts of bifidobacteria in
their stools [8]. More recently, it has been shown that infants receiving a formula low in protein and
phosphate with whey protein as the main constituent developed a bifidobacteria profile similar to that
of the breast-fed infants [9]. These studies indicate that supplementation of infant formula with specific
whey proteins may have the potential to emulate the bioactivities associated with human breast milk,
including the development of microbiota rich in beneficial bifidobacteria.
Breast milk and its constituents naturally select for protective bifidobacteria, and specific glycans
present in mammalian milk have been demonstrated to bind to and inhibit a range of enteric pathogens
in vitro [10–12]. Specific glycosylated milk components have been suggested to not only confer prebiotic
effects, but also contribute to the colonization potential of bifidobacteria spp. in the intestine by directly
modulating the intestinal cells, or by enhancing the adherence properties of the bacteria. For instance,
our group recently demonstrated a bovine milk-derived fraction containing 23.64 µg/mL IgG among
other components, including 3′- and 6′-sialyllactose, β-lactoglobulin, and α-lactalbumin, and was
capable of modulating HT-29 cells which resulted in a subsequent increase in bifibacterial adhesion of
up to 52-fold compared to the non-treated HT-29 cells [13]. Transcriptomic, proteomic, and glycomic
analysis of the intestinal cells following treatment with the bovine milk-derived fraction confirmed that
the cell surface proteome and glycome were altered [13,14]. Regarding enhancing the adherence abilities
of bifidobacteria, growth of B. longum in defatted human milk upregulated a gene encoding a putative
type II glycoprotein-binding fimbriae, which may be involved in attachment and colonization [15].
Chichlowski et al. [16] demonstrated the increased adherence of B. longum subsp. infantis ATCC 15697
(B. infantis to HT-29 intestinal cells following its growth on human milk oligosaccharides. Additionally,
our group demonstrated that treatment of B. infantis with a combination of the milk oligosaccharides,
3′-and 6′-sialyllactose significantly increased bacterial adhesion to HT-29 cells up to 9.8-fold [17].
Previously, we also demonstrated the increased adhesion of B. infantis following exposure to a panel of
oligosaccharides and a bovine whey-derived powder enriched in IgG [18]. Subsequent studies with
goat milk oligosaccharides (GMO) indicated a prophylactic protective effect against Campylobacter jejuni
colonization when HT-29 cells were pre-exposed to GMO-treated bifidobacteria [19].
Taken together, these studies indicate that glycosylated fractions from domestic animal milks
may result in an increase in bifidobacteria colonizing the gut. The term synbiotic is used to describe
the use of a combination of probiotics and prebiotics that together beneficially improve host health
by modulating the development of a healthy gut microbiota. Therefore, the current study aimed to
examine the effect of combining B. infantis with a bovine whey-derived fraction rich in IgG on the
attachment of B. infantis to intestinal cells and in turn the ability of the combination to exclude an
invasive strain of C. jejuni to intestinal cells in vitro.
2. Results
2.1. Characterization of Immunoglobulin G-enriched Powder (IGEP)
IGEP was kindly provided by Upfront technologies. The IGEP contained 77% protein as
determined by the Bradford assay [20]. SDS-PAGE analysis of the IGEP powder (Figure 1) revealed
that it mainly consisted of IgG, with two protein bands corresponding to 55 and 20 kDa representing
the IgG heavy chain and light chain, respectively.
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2.2. Effect of IGEP on B. infantis Adhesion
Bacteria were incubated with IGEP (5 mg/mL) which was suspended in McCoy’s 5A tissue culture
media as per Quinn et al. [18]. IGEP-treated B. infantis displayed a 3-fold increase in adhesion to
HT-29 cells (Figure 2). Bovine serum-derived IgG (S-IgG) had no significant effect on B. infantis
adhesion. Treatment of IGEP with sodium metaperiodate (MP-IGEP) to disable biological recognition
of the conjugated oligosaccharides in the sample abolished any increase in B. infantis adhesion
(p-value = 0.3773) [21]. Thus, the increase of adhesion of IGEP-treated B. infantis to HT-29 cells was
mediated at least in part by IGEP glycosylation.
2.3. Combined Effect of IGEP and B. infantis on C. jejuni Adhesion
Anti-infective and competitive exclusion assays were employed here to investigate if (A) IGEP had
a direct anti-infective effect on C. jejuni colonization, and (B) to determine if the increase in B. infantis
adhesion as a result of IGEP pre-treatment resulted in a protective effect against C. jejuni colonization.
An average inoculum of 4.7 × 108 colony-forming units (CFU)/mL of C. jejuni were applied to the HT-29
cells, of which 3.1 × 105 CFU/mL (0.1% ± 0.01% of the original inoculum) attached to the HT-29 cells.
We chose Campylobacter jejuni 81–176 (C. jejuni) for this study as our group has previously demonstrated
that bovine milk oligosaccharides have anti-infective effects against this strain [22]; additionally, it has
been used in many other previous studies and is well characterized [19,21]. A high inoculum of
C. jejuni was used in order to increase the opportunity of pathogenic infection of the HT-29 cells.
Anti-infective assays were implemented as previously described [22] to determine if IGEP had any
direct anti-pathogenic effects. No direct anti-infective effect was observed (p-value > 0.5) (Figure 3A).
Competitive exclusion assays were implemented in order to assess if the increased adhesion observed
in IGEP-treated B. infantis facilitated protection against pathogen colonization. First, the B. infantis
was treated with IGEP for one hour, after which the bacteria were washed and applied to the HT-29
cells for 2 h. The cell line was washed to remove non-adherent B. infantis and then challenged
with C. jejuni for 3 h prior to enumeration of colonized C. jejuni. Notably, IGEP-treated B. infantis
revealed a statistically significant reduction in C. jejuni colonization following prior treatment of the
HT-29 cells with IGEP-treated B. infantis (Figure 3B), with an average significant decrease of 48% in
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C. jejuni adherence observed. Neither B. infantis nor IGEP alone had protective effects against C. jejuni
colonization (Figure 3A,B). Notably, no growth of C. jejuni in the presence of IGEP was observed
under anti-infective and exclusion assay conditions. Overall, IGEP-treated B. infantis appears to
provide prophylactic protection against C. jejuni colonization (48% reduction); this is likely through the
increased colonization potential of B. infantis. Therefore, the combined use of IGEP and B. infantis may











































Figure 2. Adhesion of Bifidobacterium infantis to HT-29 cells following incubation with bovine
serum-derived IgG (S-IgG), whey-derived Ig enriched powder (IGEP), and metaperiodate-treated
IGEP (MP-IGEP). Results are from three biological replicate experiments, each performed in technical
triplicate, except for S-IgG and MP-IGEP treatment which were assayed in technical triplicate using
one biological replicate. Results were calculated as the percentage of adherent cells = (CFU/mL of
recovered adherent bacteria ÷ CFU/mL of inoculum) × 100, and bars represent the fold-change relative
to percent adhesion of control, with error bars representing ± one standard deviation. The Student
t-tests were used to test for significance in comparison to the control (Bifidobacteria). *, p-value < 0.05;
n.s., not significant.
2.4. B. infantis Growth in IGEP
In order to investigate if growth was implicated in the observed increase in adhesion and
consequent anti-infective activities, the ability of IGEP to stimulate the growth of B. infantis was
examined. When IGEP was incubated with B. infantis over 42 h, no significant increase in bacterial
growth was observed (Figure 4). Thus, it is unlikely that increased numbers of B. infantis contributed
to the observed increase in adhesion to the HT-29 cells after exposure to IGEP.
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Figure 3. Anti-infective assays (A) demonstrating Campylobacter jejuni 81–176 adhesion in the absence
(green) and presence (orange) of IGEP. (B) Competitive exclusion assays demonstrating C. jejuni
81–176 adhesion to HT-29 cells f llowing pre-treatment of the HT-29 cells with B. i fantis 15697 (blue)
and B. infantis 15697 pre-tr ated with IGEP (yellow). Results are represented s the average of one
biological replicate experiment performed in technical triplicate (A), and the average of three biological
replicate experiments perfor ed in technical triplicate (B), and are represented as a percentage of
adherent cells = (CFU/mL of recovered adherent bacteria ÷ CFU/mL of inoculum) × 100, and graphed
as fold-change relative to percent adhesion of control, with error bars representing ± one standard
deviation. The Student t-tests were used to test for significance in comparison to the control (A), or in
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Figure 4. Growth of B. infantis in carbohydrate-free media supplemented with IGEP over 48 h
(IGEP-supplemented) compared to a positive control of culture in de Man–Rogosa–Sharpe (MRS) with
glucose and a negative control of non-supplemented carbohydrate-free media. Optical density at
600 nm was measured at 0, 6, 12, 24, and 48 h post-inoculation. Results are represented as the average
of three replicates, with error bars representing ± one standard deviation. The Student t-tests were
used to test for significance in comparison to the negative control. *, p-value < 0.05; ***, p-value < 0.002;
n.s., not significant.
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2.5. B. infantis Metabolite Analysis
The presence of bifidobacteria in the gut influences the production of bacterial metabolites
including formate, acetate, ethanol, and lactate [23,24]. In this study, HPLC analysis was used to
quantify these metabolites in the supernatant following B. infantis growth in the presence of IGEP
(Table 1). There were no statistically significant changes in levels of acetate, lactate, formate, or ethanol
in IGEP-treated culture compared to no IGEP supplementation (control) following a 24 h fermentation,
and the ratios of acetate to lactate (4:1) and acetate to formate (2:1) were the same for both the
supplemented and non-supplemented samples. Ratios observed were likely due to carbohydrate
(glucose) in the baseline media (McCoy’s media), as these assays were performed under adhesion
assay conditions. Slight ethanol production was observed in the IGEP-supplemented sample (1:1),
while no ethanol was detected in the non-supplemented sample, and this can likely be attributed to the
IGEP composition itself.
Table 1. Metabolite analysis by B. infantis following 24 h incubation with IGEP. Concentration values
(mM) are the average of three biological replicates, each analyzed in technical triplicate.







In this study, IGEP increased the adhesion of B. infantis 3-fold to HT-29 cells. Notably, SDS-PAGE
revealed that IgG was a dominate protein in the powder, although other Igs such as IgA and IgM
may also have been present. IgG is present in human (0.1 g/L) and bovine (1.8 g/L) milk [25–27] and
immunoglobulins (Igs) represent about 10–15% of whey proteins in both milk types [28,29]. Igs are
known for their potent immunological properties and ability to inhibit gastrointestinal pathogens such
as bacteria, protozoa, and viruses [30,31]. IgG is the predominant Ig in bovine milk and is known to be
heavily glycosylated [32] and, in this respect, may also be expected to alter colonization of specific
types of bacteria. Indeed, IgG is also the most common Ig in human blood serum [33]. IgG plays a
crucial role in protective immunity and is involved in opsonization, agglutination, antibody-dependent
cell-mediated cytotoxicity, and complement-dependent cytotoxicity activation [34,35]. Three domain
structures exist in IgG; two structures are involved in antigen binding (Fab region) and the other is
the fragment crystallizable (Fc) region that activates Fcγ receptors (FcγRs) of leukocytes and the C1
component of complement. One glycosylation site at asparagine 297 (N-linked) within the Fc region of
IgG exists, in contrast to the vast array of other immunoglobulin isotypes which have more than one
glycosylation site within the Fc region [36]. The hypervariable region of the antigen-binding fragment
(Fab) of IgG has also been shown to contain N-glycans [37]. Notably, SDS-PAGE analysis of IGEP
displayed trace bands between the 116 and 55 kDa markers that could be IgA components. Increased
levels of secretory IgA (SIgA) in stools have been associated with infant formula supplemented with
probiotics [38]. The commensal Bacteroides fragilis has been previously demonstrated to modulate
binding of IgA to the intestinal mucosa suggesting that IgA may facilitate host-microbial symbiosis [39].
Additionally, SIgA has been shown to bind to mucin-producing HT29-MTX (HT-29 cells treated with
methotrexate). This binding ability was significantly less in non-mucin-producing HT-29 cells [40].
In the current study we did not use mucin-producing HT-29 cells. Moreover, while trace levels of IgA
may be present, IgG appeared to be the dominant Ig. Interestingly, the concentration of IgA is lower in
bovine milk (0.08 g/L) than in bovine blood serum (0.37 g/L) [41]. Thus, while further characterization
of the IGEP is required to fully identify the active component, considering the concentrations of
IgA present in bovine milk and the results obtained via SDS-PAGE, it is more likely that IgG may
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be modulating the observed effects; however, isotyping is required to confirm this. Nonetheless,
as periodate treatment abolished the increased adhesion of B. infantis, the glycan component of IGEP is
likely to be responsible at least in part for the strain’s enhanced adhesion to the HT-29 cells.
The importance of milk protein glycosylation on biological function has been shown previously
using glycomacropeptide (GMP). GMP, which promotes the growth of B. infantis, lost its prebiotic
effect following periodate treatment [42]. Additionally, GMP’s ability to prevent Escherichia coli and
Salmonella enteritidis intestinal infection was reduced following sialidase treatment and abolished
following periodate oxidation [43]. Notably, bovine IgG-glycans contain fucose, galactose, and mannose
structures in addition to sialic acids such as N-acetylneuraminic acid (Neu5Ac) and the non-human
N-glycolylneuraminic acid (Neu5Gc) [44]. While IGEP-bound glycans may directly influence the
adhesion of B. infants, it is important to note that B. infantis encodes an endoglycosidase, EndoBI-1
(glycosyl hydrolase family 18), which is capable of cleaving N-linked oligosaccharides on glycoproteins.
This activity could potentially release oligosaccharides bound to glycoproteins in IGEP [45], resulting in
the production of intact free oligosaccharides that could then directly influence the adhesion potential
of the strain. Notably, in this study, bovine serum-derived IgG failed to induce any increase in the
adhesion of B. infantis, suggesting that bovine milk-derived IgG may possess different glycan structures.
Glycosylation is known to be cell-type specific [46,47] and IgG produced in different cells may contain
differences in their oligosaccharide chains. In addition, the glycosylation pattern of milk-derived IgG is
known to change over lactation [44] and may in part explain the different activities observed between
serum- and milk-derived IgG.
IGEP may be influencing adhesion in a number of ways. For instance, it may induce the
increased expression of adhesion factors by the bacteria. Our group previously demonstrated that
milk oligosaccharides resulted in the increased adhesion of B. infantis to HT-29 cells. Exposure to
the milk oligosaccharides was associated with an upregulation of genes involved in adhesion, e.g.,
DNA-binding protein-ferritin, GroEL, DnaK, and TadE, and a downregulation of genes involved in
complex oligosaccharide metabolism [17]. IGEP may also aid the adhesion of B. infantis to the host
cells by acting as a bridge between the bacteria and the host cells. For example, bovine lactoferrin has
been shown to function as a molecular bridge for internalization of Streptococcus uberis into bovine
mammary epithelial cells [48]. Less likely is the possibility that residual IGEP is modulating the cell
line itself. This is unlikely as IGEP was washed from bacterial cells prior to exposure to intestinal
cells. Our group has, however, recently shown that IgG isolated from bovine colostrum and milk does
modulate the cell surface of HT-29 cells, in turn enhancing the adhesion of bifidobacteria to HT-29
cells [49].
A variety of milk-derived proteins have been shown to possess anti-infective activities. For example,
lactoferrin has antimicrobial activity [50] and displays anti-adhesive effects against pathogens such
as E. coli and enteropathogenic Yersinia [51,52]. Lactoferrin also has been reported to promote the
growth of various lactobacilli [53]. Previously, milk-fat globule membrane glycoproteins have been
shown to have anti-adhesive properties against a range of pathogens, including rotavirus and various
enteric bacteria [54,55]. Notably, sialic acid on some milk glycoproteins have been implicated in
binding E. coli and Salmonella enteritidis [43,56], increasing growth of the bifidobacterial spp. such as
B. breve, B. bifidum, B infantis [57], and preventing Helicobacter pylori colonization [58]. IgG in milk is
responsible for agglutinating bacteria, neutralizing toxins, deactivating viruses, binding pathogens
such as Shigella flexneri, E. coli, Clostridium difficile, and rotavirus [59,60], and developing an environment
favorable for the growth of health-promoting bacteria [61]. In this study, 0.1% ± 0.01 of C. jejuni of
the original inoculum adhered to the HT-29 cells, which is similar to the 0.25% ± 0.05 observed in
a previous study by our group [19]. Interestingly, no protective effect was observed for IGEP alone,
which was unexpected as IgA in breast milk has been associated with lower rates of Campylobacter in
children [62]. This may be a result of the short exposure period of the pathogen to the IGEP throughout
the anti-infective assays.
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C. jejuni infection is prevalent in commercial broiler chickens in addition to swine, cattle,
and contaminated water, and these sources act as a major reservoir that can result in human infection [63].
In this study, a combination of B. infantis and whey protein-derived IGEP resulted in a 48% decrease
in pathogen colonization following prior treatment of the HT-29 cells with IGEP-treated B. infantis.
Notably, the non-supplemented B. infantis control demonstrated no protective effect against C. jejuni
colonization, in line with previous results that suggested a critical number of attached bifidobacteria are
required to competitively exclude C. jejuni [19]. IGEP-treated B. infantis may result in the appropriate
numbers interacting with the cell, which, in turn, may result in modulation of the HT-29 cells. C. jejuni
is known to enter the gut epithelial cells and impair intestinal barrier function through cleavage of
occludin by serine protease HtrA [64]. Notably, HMO-grown B. infantis is associated with a higher
adhesion rate to HT-29 cells and has been shown to influence the expression of the epithelial cell
surface receptors and immune responses [16]. In addition, occludin expression in Caco-2 cells is higher
when exposed to HMO-grown B. bifidum [16]. Thus, protection against C. jejuni colonization could
result from modulation of gene expression on the epithelial cells through exposure to IGEP-treated
B. infantis. Previously, we demonstrated that an increase in adhesion induced by GMO had a protective
effect against C. jejuni colonization of HT-29 cells in pathogen exclusion assays [19]. While no direct
anti-infective effect was observed in this study, the concept that probiotics and pathogenic strains
compete in the gastrointestinal tract for host cells surface receptors and nutrients has been well
documented [65,66]. Bacteria such as Lactobacillus spp., i.e., acidophilus, casei, crispatus, gasseri, helveticus,
pentosus, plantarum, rhamnosus, and salivarius have been suggested to exhibit anti-Campylobacter activities
in vitro and in vivo [63,67]. In vivo studies using galactooligosaccharides/B. longum PCB 133 synbiotics
have shown potential in reducing C. jejuni infection in poultry [68]. In addition, a microencapsulated
B. longum PCB133 and xylooligosaccharides synbiotic can protect against C. jejuni infection in broiler
chickens [69], and L. salivarius subsp. salicinius combined with 0.04% mannan oligosaccharides have
demonstrated a decrease (3 log) in broiler chicken cecal Campylobacter levels [70]. While previous
studies focused on pathogen protection using free glycans in synbiotics combinations, the use of milk
glycoproteins also holds promise.
This study is particularly relevant considering the prevalence of Campylobacter and the fact that it is
recognized as one of four key global causes of diarrheal diseases. Indeed, it is considered to be the most
common bacterial cause of human gastroenteritis in the world and has an associated risk of secondary
post-infection diseases such as irritable bowel syndrome and Guillain-Barre syndrome [21,71,72].
Further studies with other probiotic strains and pathogens are required to determine if this bioactivity
can be extended to protect against other diseases.
IGEP did not demonstrate any significant influence on the growth of B. infantis or metabolite
production following 24 h incubation with the strain and no statistically significant difference between
the supplemented sample and non-supplemented sample were observed. This was somewhat
unexpected as IGEP contains glycoproteins, and B. infantis has evolved to utilize milk glycans [73].
However, metabolite analysis showed growth on IGEP resulted in slightly higher levels of acetate,
lactate and decreased levels of formate (Table 1). Additionally, low levels of ethanol, which were
not detected in the non-supplemented sample were also observed. This may suggest that the level
of glycans present in IGEP are too low to support growth. Notably, previous work in our lab has
shown that growth on oligosaccharides isolated from goats milk results in slight ethanol production
by bifidobacteria [19]. Therefore, this result is not surprising as the presence of bifidobacteria in the
gut has been demonstrated to influence the production of formate, acetate, ethanol and lactate [23],
and some bifidobacteria convert pyruvic acid into formic acid and ethanol as opposed to lactic acid,
yielding an additional ATP [24]. Overall, these data indicate that IGEP did not significantly influence
B. infantis metabolite production in vitro and that the altered adhesion of B. infantis when cultured in
the presence of IGEP was not due to growth of the strain.
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4. Materials and Methods
4.1. Materials and Bacterial Strains
The IGEP was kindly provided by Upfront Chromatography (Copenhagen, Denmark). The protein
content of the powder was determined by the Bradford assay [20]. B. longum subsp. infantis ATCC®
15697™ (B. infantis) was obtained from the American Type Culture Collection (ATCC, Middlesex, UK).
C. jejuni 81–176 was kindly provided by Dr Marguerite Clyne’s, University College Dublin.
4.2. Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis (SDS-PAGE) Analysis
Sample preparation and reduction was performed as per the manufacturer’s instructions (NuPAGE
system, Life Technologies, Thermo Fisher Scientific Inc.). In brief, 7.5 µL of sample buffer, 3 µL of
reducing agent, and 12 µL of deionized water were added to 7.5 µL of sample at 10 mg/mL (by mass of
powder) to give a final volume of 30 µL and a total of 15 µg of protein/well. The sample was then
centrifuged and heated to 70 ◦C for 10 min, and 10 µL of sample was added to each well of a 4–12%
Bis-Tris gel (1.00 mm × 9 well, Life Technologies). A molecular weight standard solution (Invitrogen
Mark12 Unstained Standard, Thermo Fisher Scientific Inc.), was prepared as per the manufacturer’s
instructions (diluted 1:10 with Invitrogen LDS Sample Buffer) and loaded onto the gel. Electrophoresis
was performed at 200 V for 50 min using MOPS buffer supplemented with 0.25% NuPAGE Antioxidant
(Life Technologies) in the upper chamber. Protein bands were visualized on the gels using Coomassie
Blue stain (Invitrogen SimplyBlue SafeStain) following the manufacturer’s procedure.
4.3. Periodate Treatment of Powder
Sodium metaperiodate (NaIO4) treatment of IGEP was performed to oxidize IGEP andproduce
IGEP-P as previously described [21]. In brief, IGEP (10 mg/mL) was incubated with 0.011 mM NaIO4 at
4 ◦C for 30 min. To remove excess NaIO4, the sample was centrifuged using a 3 kDa MWCO (Amicon)
with three washes of phosphate-buffered saline at pH 7.4 (PBS). The retentate collected contained the
IGEP and was lyophilized to produce a powder. A negative control containing no IGEP, and a control
sample not treated with NaIO4 were also included.
4.4. Bacterial Culture
Bacterial cultures were maintained as previously described [17,18]. B. infantis was stored in
de Man–Rogosa–Sharpe (MRS) (Difco, Sparks, MD, USA) broth containing 50% glycerol at −80 ◦C.
The strain was cultured twice in MRS media supplemented with L-cysteine (0.05% w/v) (Merck,
Dannstadt, Germany) prior to use, and was routinely grown overnight at 37 ◦C under anaerobic
conditions generated using an Anaerocult A system (Merck, Dannstadt, Germany).
C. jejuni 81–176 was stored in Mueller Hinton broth (Oxoid, Ireland c/o Fannin Healthcare, Dublin,
Ireland) containing 50% glycerol at −80 ◦C and cultured directly from storage onto Mueller-Hinton
agar plates. The pathogen was grown under microaerophilic conditions generated using CampyGen
gas packs (Oxoid), for 48 h at 37 ◦C as previously described [19,22]. Prior to pathogen inhibition
assays, C. jejuni 81–176 was grown on Mueller-Hinton agar and then transferred to biphasic media
in 25 cm2 tissue culture flasks (Corning, New York, NY, USA) consisting of Mueller-Hinton agar
supplemented with Campylobacter selective supplement (Skirrow), (Oxoid) and 6 mL of McCoy’s 5A
media (Merck) supplemented with 2% fetal bovine serum (FBS). The flask was then incubated for 24 h
under microaerophilic conditions at 37 ◦C.
4.5. Exposure of B. infantis to IGEP for Adhesion Assays
Exposure of the bacteria to IGEP was performed as previously described [18,19]. Bacteria were
used at mid-exponential growth phase (18 h), and the OD600nm was adjusted to 0.3 at the start of the
assay, after which the cells were cultured for 1.5–2 h and used once an OD600nm of 0.5 was reached
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(corresponding to approximately 1.6 × 108 CFU/mL). Bacterial cells were washed twice with PBS
by centrifugation (3850× g, 5 min). Cell pellets were re-suspended to a final OD600nm of 0.25 in
non-supplemented, or IGEP-supplemented McCoy’s 5A tissue culture media. A final concentration
of 5 mg/mL as per Quinn et al. [18] was used. Bacterial suspensions were then incubated for 1 h at
37 ◦C under anaerobic conditions. Following this, bacteria were harvested by centrifugation (3850× g,
5 min), the supernatants removed, and pellets were washed three times in PBS and then re-suspended
in non-supplemented McCoy’s media prior to use in the adhesion assays.
4.6. Mammalian Cell Culture Conditions
HT-29 cells were grown as previously described [18,19] and maintained in McCoy′s 5A modified
medium (Merck) supplemented with 10% FBS using 75 cm2 tissue culture flasks incubated at 37 ◦C in
5% CO2 in a humidified atmosphere. Once the cells were nearing confluency (approximately 80–90%),
they were passaged into 48-well tissue culture plates (Sarstedt Ltd., Wexford, Ireland) at a density of
1 × 105 cells/mL between passages 15–21. The cells were then used once fully confluent (approximately
2 × 106 cells/well). The media was changed every other day and supplemented with 2% FBS 24 h prior
to use.
4.7. Adhesion Assays with B. infantis
Adhesion assays with B. infantis were performed as previously described [18,19]. HT-29 cells were
washed twice with PBS, and 250 µL of the bacteria and media suspensions were added to the wells,
corresponding to approximately 40 bacterial cells per human cell. Bacterial cells were incubated with
the HT-29 cells for 2 h at 37 ◦C under anaerobic conditions using an Anaerocult A system (Merck).
The HT-29 cells were then washed five times with PBS to remove non-adherent bacteria. HT-29 cells
were then lysed with 250 µL of 1% TritonTM X-100 (Merck) for 5 min at 37 ◦C. The lysates were serially
diluted and enumerated by spot-plating on MRS plates to enumerate bacterial colony-forming units
(CFU). The adhesion of the bacteria was determined as the percentage of original inoculum which
attached, thus accounting for variations in the starting inoculum. Percentage adhesion = (CFU/mL of
recovered adherent bacteria/CFU/mL of inoculum) × 100. Experiments were performed in triplicate on
three separate occasions.
4.8. Anti-Infective Assays and Exclusion Assay
Anti-infective assays were performed as previously described [19,22]. In brief, C. jejuni was
incubated in the absence and presence of IGEP (5 mg/mL) at a final OD600nm of 0.3 (approximately
4.7 × 108 CFU/mL) in McCoys’s media and incubated under microaerophilic conditions for 1 h at 37 ◦C;
250 µL of the mix was then applied to three wells containing HT-29 cells, and allowed to incubate for
3 h, after which the eukaryotic cells were washed five times with PBS, lysed with 250 µL 0.1% Triton
X-100 in PB, plated onto Mueller-Hinton agar plates, and incubated under microaerophilic conditions
for 72 h at 37 ◦C to enumerate CFU. For exclusion assays, exposure of B. infantis to 5 mg/mL IGEP was
performed as described above, and this suspension was subsequently incubated with the HT-29 cells
for 2 h. A non-supplemented control was also included. Non-adherent bacteria were removed from the
cells as described above, after which the cell line was challenged with C. jejuni. To do this, the pathogen
was harvested from the biphasic medium, washed twice in non-supplemented McCoy’s, and diluted to
an OD600nm of 0.3. From this suspension, 250 µL was then added to each well, and cells were incubated
under anaerobic conditions for 3 h at 37 ◦C. Cells were then washed five times with PBS, lysed with
0.1% Triton X-100 in PBS, and plated onto supplemented Mueller-Hinton agar. Mueller-Hinton plates
were incubated under microaerophilic conditions for 72 h at 37 ◦C, after which bacterial CFU were
enumerated. For anti-infective assays and competitive exclusion assays, all results are presented as the
mean of biological replicate experiments, with error bars representing standard deviation, graphed as
fold-change relative to percent adhesion of the control. Percentage adhesion = (CFU/mL of recovered
adherent bacteria ÷ CFU/mL of inoculum) × 100.
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4.9. Effect of IGEP on the Growth of B. infantis
B. infantis was grown in the absence and presence of 5 mg/mL IGEP over a 48 h period under
adhesion assay conditions and in carbohydrate-free growth medium; de Man–Rogosa–Sharpe (MRS)
supplemented with L-cysteine (0.05% w/v) was prepared by the first principles excluding glucose and
meat extract [74,75]. Carbohydrate-free MRS was unable to support bacterial growth above an OD600nm
of 0.2. The optical density readings between supplemented and un-supplemented carbohydrate-free
media were noted and the difference between these was recorded as the turbidity of the sample,
and this was added to all control sample readings to correct the difference in optical density. Aliquots
of 150 µL of the bacterial suspensions were added to the individual wells of a 96-well microtiter
plate corresponding to an optical density of 0.03. Other controls included a control containing no
bacteria, and bacteria were grown in MRSbroth supplemented with L-cysteine (0.05% w/v) (Merck).
These experiments were performed in an anaerobic hood and bacterial growth was monitored by
determining absorbance (OD600nm) at 0, 12, 24, and 48 h. The microtitre plate was automatically
shaken for 30 s prior to each measurement to achieve a homogenous suspension. Experiments under
adhesion assay conditions were performed in triplicate on three separate occasions and in triplicate
under carbohydrate free-MRS conditions. The percentage change in growth was calculated as the
difference in OD600nm between the supplemented and non-supplemented samples.
4.10. B. infantis Metabolite Analysis
Metabolite analysis was conducted as previously described [19]. B. infantis was grown overnight
under the optimal conditions outlined above and then re-suspended in McCoy’s media at an OD600nm
of 0.25 with a final oligosaccharide concentration of 5 mg/mL. A one milli-litre aliquot of this cell
suspension was then dispensed into a sterile Eppendorf after 0 and 24 h of growth. A negative control
containing no bacteria was also included. These solutions were then centrifuged for 5 min (3850× g)
and the supernatants collected. The process was repeated three times to ensure that bacteria were not
present in the supernatant. The sample was also treated with ultraviolet light for 30 min in a laminar
flow hood to ensure no further metabolic activity occurred [19]. The metabolic-end products (lactate,
acetate, formate, and ethanol) in the supernatant were measured in triplicate using an Agilent 1200
HPLC system (Agilent Technologies, Santa Clara, CA, USA) with a refractive index detector. A negative
control of non-supplemented media was also included. A REZEX 8 m 8% H, organic acid column
(300 × 7.8 mM Phenomenex, CA, USA) was used and the elution was performed for 25 min with a
0.01 M H2SO4 solution at a constant flow rate of 0.6 mL/min and a temperature of 65 ◦C. Metabolite
peaks and concentrations were identified and calculated based on known metabolite retention times
and standard solutions at known concentrations. The ratios of acetate to lactate, acetate to formate,
and lactate to ethanol were also calculated.
4.11. Statistical Analysis
Graphs were drawn using Microsoft Excel. The results are presented as the mean ± standard
deviations of replicate experiments, and the Student t-tests were used to determine statistically significant
results in comparison to the control. For all experiments, p-value < 0.05 was considered significant.
5. Conclusions
Exposure of B. infantis to IGEP resulted in an increased attachment to HT-29 cells and was in
part mediated by IGEP glycosylation. This synbiotic combination ultimately led to protection against
C. jejuni colonization of HT-29 cells in vitro. This is a particularly beneficial outcome as Campylobacter
is recognized in both developed and developing counties as a leading cause of diarrheal diseases and
is most common in children younger than five years of age [71,76]. Animal reservoirs are the most
common source of Campylobacter infection, with 60% to 80% of broiler chicken flocks estimated to be
contaminated with Campylobacter at slaughter [77], and a suggested 48% of Campylobacter infections are
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thought to be related poultry exposure [78]. Consequently, host protection via competitive exclusion
by commensals has the potential to reduce the rising numbers of Campylobacter infections in humans
and could be extended for use in livestock animal feed to reduce the rates of transmission from such
reservoirs. Moreover, the use of synbiotics such as IGEP in combination with probiotic bacteria have
potential to be used as a means to protect against other gastrointestinal pathogens. Overall, this study
highlights the benefits of using a combination of probiotic bacteria and IgG-enriched whey to promote
overall gut health, and indicates that synbiotic combinations may hold superior health-promoting
properties when compared with either probiotics or prebiotics when used alone.
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